Last reviewed · How we verify
Amoxicillin/clavulinic acid
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes. Used for Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media), Community-acquired pneumonia, Acute bacterial sinusitis.
At a glance
| Generic name | Amoxicillin/clavulinic acid |
|---|---|
| Sponsor | Pfizer |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamase enzymes, preventing them from breaking down amoxicillin and extending its spectrum of activity against beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media)
- Community-acquired pneumonia
- Acute bacterial sinusitis
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reaction
Key clinical trials
- The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures (PHASE1)
- A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin/clavulinic acid CI brief — competitive landscape report
- Amoxicillin/clavulinic acid updates RSS · CI watch RSS
- Pfizer portfolio CI